Long-Term Treatment of Collagenous Colitis With Budesonide

• Status: Unknown status
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the trial is to examine the effect of budesonide treatment on collagenous colitis. All patients is treated for 6 weeks with budesonide and thereafter randomised to 24 weeks treatment with placebo or continued budesonide. The end poit is effect on clinical symptoms (number of daily stools)

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bonderup, Ole K., M.D.
• Collaborator: AstraZeneca
• Treatments: Budesonide

Criteria

Inclusion Criteria:

• Histological criteria of Collagenous colitis

• Clinical activity (> 3 stools/day)

Exclusion Criteria:

• Treatment of Collagenous colitis within the last 3 months